$2.42 Billion is the total value of Novo Holdings A/S's 51 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 18.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INGN | Sell | INOGEN INC | $144,919,000 | -8.6% | 2,759,320 | -22.3% | 5.98% | -12.0% |
| HRMY | Sell | HARMONY BIOSCIENCES HLDGS IN | $110,234,000 | -15.8% | 3,336,378 | -7.9% | 4.55% | -18.9% |
| CABO | Sell | CABLE ONE INC | $86,556,000 | -25.8% | 47,341 | -9.6% | 3.57% | -28.5% |
| INZY | Sell | INOZYME PHARMA INC | $38,994,000 | -26.5% | 1,969,379 | -23.4% | 1.61% | -29.2% |
| SPNE | Sell | SEASPINE HLDGS CORP | $22,986,000 | -1.6% | 1,321,006 | -1.4% | 0.95% | -5.3% |
| GRTX | Sell | GALERA THERAPEUTICS INC | $21,689,000 | -28.4% | 2,459,021 | -16.9% | 0.90% | -31.0% |
| AERI | Sell | AERIE PHARMACEUTICALS INC | $14,089,000 | +29.1% | 788,410 | -2.4% | 0.58% | +24.4% |
| VRNA | Sell | VERONA PHARMA PLCsponsored ads | $7,009,000 | -61.6% | 838,360 | -67.9% | 0.29% | -63.1% |
| SPRO | Sell | SPERO THERAPEUTICS INC | $6,902,000 | -38.3% | 468,902 | -18.7% | 0.28% | -40.5% |
| CRVS | Exit | CORVUS PHARMACEUTICALS INC | $0 | – | -847,906 | -100.0% | -0.13% | – |
| CTLT | Exit | CATALENT INC | $0 | – | -997,349 | -100.0% | -4.45% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VANGUARD INDEX FDS | 41 | Q3 2022 | 64.7% |
| INOGEN INC | 34 | Q2 2022 | 68.8% |
| VANGUARD INTL EQUITY INDEX F | 29 | Q4 2016 | 37.6% |
| AMICUS THERAPEUTICS INC | 22 | Q3 2023 | 4.1% |
| AKEBIA THERAPEUTICS INC | 21 | Q3 2020 | 4.8% |
| VERONA PHARMA PLC | 21 | Q2 2022 | 1.9% |
| CORVUS PHARMACEUTICALS INC | 20 | Q4 2020 | 7.1% |
| INSPIRE MED SYS INC | 20 | Q3 2023 | 1.8% |
| CABLE ONE INC | 19 | Q3 2023 | 9.7% |
| FLEXION THERAPEUTICS INC | 19 | Q3 2021 | 4.7% |
View Novo Holdings A/S's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyteir Therapeutics, Inc. | August 03, 2023 | 1,547,136 | 4.4% |
| Disc Medicine, Inc. | June 28, 2023 | 1,090,772 | 4.8% |
| Galera Therapeutics, Inc. | June 28, 2023 | 2,100,000 | 4.9% |
| VectivBio Holding AGSold out | May 26, 2023 | 0 | 0.0% |
| LanzaTech Global, Inc. | February 17, 2023 | 15,814,845 | 8.1% |
| Bolt Biotherapeutics, Inc.Sold out | January 04, 2023 | 0 | 0.0% |
| Arcellx, Inc. | December 12, 2022 | 1,750,000 | 4.0% |
| MINERVA SURGICAL INC | November 03, 2022 | 1,322,473 | 4.5% |
| Milestone Pharmaceuticals Inc. | October 24, 2022 | 1,378,538 | 4.6% |
| Galecto, Inc. | September 30, 2022 | 2,497,791 | 9.8% |
View Novo Holdings A/S's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 144 | 2024-05-10 |
| SC 13D/A | 2024-03-28 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 144 | 2024-03-18 |
| 4 | 2024-03-18 |
| SC 13D/A | 2024-03-18 |
| 144 | 2024-03-14 |
View Novo Holdings A/S's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.